Charlotte's Web (CWBHF) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
13 May, 2026Executive summary
Q1 2026 revenue was $11.2 million, down 9% year-over-year, mainly due to retail channel restructuring and a shift to a margin-accretive distributor model.
Net loss widened to $13.1 million ($0.08/share), compared to $6.2 million ($0.04/share) in Q1 2025, driven by a significant non-cash loss on financial instruments.
Announced a proposed transaction with BAT to convert a C$75.3 million ($54M) debenture and invest an additional $10 million in equity, eliminating ~$65 million in debt and reducing annual interest costs by $3 million, pending shareholder and TSX approval.
CMS activated the BEI program, enabling eligible hemp-derived CBD products to be covered for select Medicare/Medicaid beneficiaries.
Focused on advancing medical and healthcare-practitioner channels, expanding product portfolio, and launching a practitioner portal.
Financial highlights
Total assets at March 31, 2026 were $70.7 million, down from $75.3 million at year-end 2025.
Cash and cash equivalents were $5.2 million at quarter-end, down from $8.0 million at December 31, 2025 and $19.4 million a year ago.
SG&A expenses declined 17.7% year-over-year to $9.5 million, reflecting cost optimization and exit from the MLB agreement.
Net cash used in operating activities was $2.8 million, nearly flat year-over-year.
Convertible debenture principal was $63.8 million, with a net carrying amount of $51.5 million.
Outlook and guidance
Management expects gross margin to trend toward 50% as in-house production efficiencies scale and transitional costs normalize.
SG&A is expected to remain around $10 million per quarter, reflecting a leaner cost base and continued cost containment.
Liquidity is expected to strengthen significantly upon completion of the BAT transaction, with sufficient cash to fund operations for the next 12 months.
Long-term liquidity will depend on revenue growth, expense management, and successful completion of the BAT transaction.
Early phase of BEI program is implementation-led, with adoption visibility expected in the second half of 2026.
Latest events from Charlotte's Web
- Q2 2026 saw revenue drop, margin expand, and a major equity conversion strengthen the balance sheet.CWBHF
Q2 2026 - Market-leading CBD innovator, recapitalized for growth and positioned for regulatory-driven expansion.CWBHF
Investor presentation - All resolutions passed, with BAT gaining 40% ownership and a Medicare pilot seen as a major growth driver.CWBHF
AGM 2026 - Returned to growth as the #1 CBD brand, leveraging innovation, partnerships, and regulatory momentum.CWBHF
Investor presentation - Shareholders to vote on BAT transaction, director elections, and key governance matters.CWBHF
Proxy filing - Key votes include director elections and a debenture amendment that may shift company control.CWBHF
Proxy filing - Shareholders to vote on BAT's conversion to a control person, reshaping ownership and governance.CWBHF
Proxy filing - Transformed balance sheet, renewed growth, and Medicare pilot position drive future upside.CWBHF
Q4 2025 - Sequential revenue growth and cost cuts signal a turnaround amid regulatory challenges.CWBHF
Q2 2024